Oculis

52 articles about Oculis

• 

  BioSpace Global Roundup, Sept. 24

  9/24/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

• Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications

  7/27/2020

  Oculis S.A., a biopharmaceutical company focused on developing transformative topical (eye drop) ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for OCS-01 in two indicat

• Oculis Reports Positive Top-line Data From SKYGGN (Phase 2) Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery

  5/18/2020

  - OCS-01 meets primary endpoints demonstrating superior efficacy and safety vs vehicle in the treatment of inflammation and pain following cataract surgery with a once-daily regimen - SKYGGN is the second positive trial with OCS-01 highlighting its potential for treating both front-of-the-eye and retinal diseases such as DME - Positive results validate the Solubilizing NanoParticle (SNP) formulation technology in developing topical treatments for front-of-the-eye with less fr

• Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery at Upcoming ASCRS Annual Meeting 2020

  5/7/2020

  Oculis S.A. announces that a presentation of results from its Phase 2 clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, will be made at the American Society of Cataract and Refractive Surgery Annual Meeting, which will be held online on May 16-17, 2020.

• 

  BioSpace Movers & Shakers, March 6

  3/6/2020

  Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week's Movers & Shakers.

• Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer

  3/3/2020

  Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments for ophthalmic diseases, announced the appointment of Marcia de Souza Lima, M.D., M.I.P.P., as Chief Medical Officer.

• 

  Clinical Catch-Up: February 10-14

  2/17/2020

  It was a very busy week for clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: October 7-11

  10/14/2019

  It was a busy week for clinical trial announcements. Here’s a look.

• Oculis Strengthens its Global Clinical and Business Development Capabilities through Strategic Appointments to Senior Management Team

  11/20/2018

  Oculis announces the appointments of Fabio Baschiera PharmD, MPh, Ph.D. as Vice President of Clinical Development, and Louie-Anne Gauthier M.Sc., as Vice President of Strategic Marketing, Business Development and Licensing.

• Oculis appoints World-renowned Ophthalmology Specialist Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board

  9/24/2018

  Oculis, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings extensive clinical experience.

• Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases

  1/4/2018

  The financing was led by a syndicate of leading international life science investors including Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners.

• Oculis Completes Series A Financing

  8/16/2016